Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations

23 Feb 2022

Abstract excerpt

High-grade serous ovarian cancer (HGSOC), the most frequent and lethal form of ovarian cancer, exhibits homologous recombination deficiency (HRD) in 50% of cases. In addition to mutations in BRCA1 and BRCA2, which are the best known thus far, defects can also be caused by diverse alterations to homologous recombination-related genes or epigenetic patterns. HRD leads to genomic instability (genomic scars) and is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Plant Virus Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35267439
DOI: 10.3390/cancers14051132

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsPMID 35267439Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?Semantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literatureSemantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP InhibitorsSemantic proximity Read ↗

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnosticsSemantic proximity Read ↗

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian CarcinomasSemantic proximity Read ↗

Homologous Recombination Proficiency in High-Grade Serous Epithelial Ovarian Cancer Tumors: The Dark Side of the MoonSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and TreatmentSemantic proximity Read ↗

In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot studySemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.